Decision-analytic evaluation of the clinical effectiveness and cost-effectiveness of management programmes in chronic heart failure

European Journal of Heart Failure

Volumn 10, Issue 10, 2008, Pages 1026-1032

  Göhler, Alexander ^a,b,c   Conrads Frank, Annette ^a,c   Worrell, Stewart S ^a   Geisler, Benjamin P ^a,c   Halpern, Elkan F ^a   Dietz, Rainer ^b   Anker, Stefan D ^b   Gazelle, G Scott ^a,d   Siebert, Uwe ^a,c,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c University for Health Science   (Austria)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cost effectiveness analysis; Hearth failure; Management programme; Markov model

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; FEMALE; HEALTH CARE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH PROGRAM; HEALTH SURVEY; HEART FAILURE; HOSPITALIZATION; HUMAN; LIFE EXPECTANCY; LIFESPAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; ONSET AGE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SEX DIFFERENCE;

AGED; CHRONIC DISEASE; DECISION SUPPORT TECHNIQUES; FEMALE; HEART FAILURE; HUMANS; LIFE EXPECTANCY; MALE; MARKOV CHAINS; MODELS, STATISTICAL; PROGRAM DEVELOPMENT; PROGRAM EVALUATION; QUALITY-ADJUSTED LIFE YEARS;

EID: 53249107184     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2008.07.018     Document Type: Article

References (30)

1. Cleland J.G., Swedberg K., Follath F., et al. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 24 5 (2003) 442-463
2. Jong P., Demers C., McKelvie R.S., and Liu P.P. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol. 39 3 (2002) 463-470
3. Ryden-Bergsten T., and Andersson F. The health care costs of heart failure in Sweden. J Intern Med 246 3 (1999) 275-284
4. McAlister F.A., Stewart S., Ferrua S., and McMurray J.J. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol 44 4 (2004) 810-819
5. Gohler A., Januzzi J.L., Worrell S.S., et al. A systematic meta-analysis of the efficacy and heterogeneity of disease management programs in congestive heart failure. J Card Fail 12 7 (2006) 554-567
6. Wolinsky F.D., Overhage J.M., Stump T.E., Lubitz R.M., and Smith D.M. The risk of hospitalization for congestive heart failure among older adults. Med Care 35 10 (1997) 1031-1043
7. Briggs A.H., Claxton C., and Sculpher M. Decision Modelling for Health Economic Evaluation (2006), Oxford University Press
8. The Beta-Blocker Evaluation of Survival Trial I. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344 22 (2001) 1659-1667
9. Statistisches_Bundesamt. http://wwwdestatisde/themen/d/thm_bevoelkphp.
10. Goehler A, Geisler BP, Manne JM, et al. Utility Estimates for Decision-Analytic Modeling in Chronic Heart Failure - Health States Based on NYHA Classes and Number of Rehospitalizations. Value Health [Electronic publication ahead of print].
11. German_DRG_Grouper. wwwgdrgde.
12. Komajda M., Follath F., Swedberg K., et al. The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 24 5 (2003) 464-474
13. Rote_Liste. http://wwwrote-listede/.
14. Rich M.W., Beckham V., Wittenberg C., Leven C.L., Freedland K.E., and Carney R.M. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 333 18 (1995) 1190-1195
15. Stewart S., Vandenbroek A.J., Pearson S., and Horowitz J.D. Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure.[see comment]. Arch Intern Med 159 3 (1999) 257-261
16. Krauth C., Hessel F., Hansmeier T., Wasem J., Seitz R., and Schweikert B. [Empirical standard costs for health economic evaluation in Germany - a proposal by the working group methods in health economic evaluation]. Gesundheitswesen 67 10 (2005) 736-746
17. Angermann C., Störk S., Gelbrich G., Faller H., Jahns R., and Ertl G. A prospective randomized controlled trial comparing the efficacy of a standardized, supraregionally transferable program for monitoring and education of patients with systolic heart failure with usual care - the Interdisciplinary Network for Heart Failure (INH) study. European Society for Cardiology Annual Congress; Vienna (2007)
18. Levy A.R., Briggs A.H., Demers C., and O'Brien B.J. Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada. Am Heart J 142 3 (2001) 537-543
19. Paul S.D., Kuntz K.M., Eagle K.A., and Weinstein M.C. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch Intern Med 154 10 (1994) 1143-1149
20. Ledwidge M., Barry M., Cahill J., et al. Is multidisciplinary care of heart failure cost-beneficial when combined with optimal medical care?. Eur J Heart Fail 5 3 (2003) 381-389
21. Gregory D., Kimmelstiel C., Perry K., Parikh A., Konstam V., and Konstam M.A. Hospital cost effect of a heart failure disease management program: the Specialized Primary and Networked Care in Heart Failure (SPAN-CHF) trial. Am Heart J 151 5 (2006) 1013-1018
22. Sidorov J. Reduced health care costs associated with disease management for chronic heart failure: a study using three methods to examine the financial impact of a heart failure disease management program among medicare advantage enrollees. J Card Fail 12 8 (2006) 594-600
23. Galbreath A.D., Krasuski R.A., Smith B., et al. Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure. Circulation. 110 23 (2004) 3518-3526
24. Smith B., Hughes-Cromwick P.F., Forkner E., and Galbreath A.D. Cost-effectiveness of telephonic disease management in heart failure. Am J Manag Care 14 2 (2008) 106-115
25. Chan D.C., Heidenreich P.A., Weinstein M.C., and Fonarow G.C. Heart failure disease management programs: a cost-effectiveness analysis. Am Heart J 155 2 (2008) 332-338
26. Hirth R.A., Chernew M.E., Miller E., Fendrick A.M., and Weissert W.G. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Mak 20 3 (2000) 332-342
27. Edelson J., Weinstein M., Tosteson A., Williams L., Lee T., and Goldman L. Long-term cost-effectiveness of various intial monotherapies for mild to moderate hypertension. JAMA 263 (1990) 407-413
28. Stange P., and Summer A. Predicting treatment costs and life expectancy for end-stage renal disease. N Engl J Med 298 (1978) 372-378
29. Göhler A., Dietz R., Osterziel K.J., and Siebert U. Systematic review of decision models in heart failure treatment. Eur Heart J 26 Supplement 1 (2005) 598
30. Siebert U. The role of decision-analytic models in the prevention, diagnosis and treatment of coronary heart disease. Z Kardiol 91 Suppl 3 (2002) 144-151